Abacavir (BioDeep_00000002759)

 

Secondary id: BioDeep_00001868188

human metabolite blood metabolite Chemicals and Drugs


代谢物信息卡片


4R-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1S-methanol, monohydrochloride

化学式: C14H18N6O (286.1542)
中文名称: 阿巴卡韦
谱图信息: 最多检出来源 Homo sapiens(blood) 40.53%

分子结构信息

SMILES: C1=C[C@@H](C[C@@H]1CO)n1cnc2c(NC3CC3)nc(N)nc12
InChI: InChI=1S/C14H18N6O/c15-14-18-12(17-9-2-3-9)11-13(19-14)20(7-16-11)10-4-1-8(5-10)6-21/h1,4,7-10,21H,2-3,5-6H2,(H3,15,17,18,19)

描述信息

Abacavir is only found in individuals that have used or taken this drug. It is a powerful nucleoside analog reverse transcriptase inhibitor (NRTI) used to treat HIV and AIDS. [Wikipedia]Abacavir is a carbocyclic synthetic nucleoside analogue. Intracellularly, abacavir is converted by cellular enzymes to the active metabolite carbovir triphosphate, an analogue of deoxyguanosine-5-triphosphate (dGTP). Carbovir triphosphate inhibits the activity of HIV-1 reverse transcriptase (RT) both by competing with the natural substrate dGTP and by its incorporation into viral DNA.
J - Antiinfectives for systemic use > J05 - Antivirals for systemic use > J05A - Direct acting antivirals > J05AF - Nucleoside and nucleotide reverse transcriptase inhibitors
C471 - Enzyme Inhibitor > C1589 - Reverse Transcriptase Inhibitor > C97452 - Nucleoside Reverse Transcriptase Inhibitor
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D018894 - Reverse Transcriptase Inhibitors
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents
D009676 - Noxae > D000963 - Antimetabolites > D015224 - Dideoxynucleosides
D004791 - Enzyme Inhibitors > D019384 - Nucleic Acid Synthesis Inhibitors
C254 - Anti-Infective Agent > C281 - Antiviral Agent

同义名列表

12 个代谢物同义名

4R-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1S-methanol, monohydrochloride; {(1S-cis)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl}methanol; [(1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl]methanol; (1S,4R)-4-(2-Amino-6-(cyclopropylamino)-9H-purin-9-yl)-2-cyclopentene-1-methanol; {4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl}methanol; Abacavir succinate; Abacavir Sulfate; Abacavir; 1592U89; Ziagen; ABC; Abacavir



数据库引用编号

20 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(1)

BioCyc(0)

PlantCyc(0)

代谢反应

53 个相关的代谢反应过程信息。

Reactome(52)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(1)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表
Cytoplasm 4 ABCB1, ALB, P2RX7, SRY
Peripheral membrane protein 1 CYP1B1
Endosome membrane 2 HLA-A, HLA-B
Endoplasmic reticulum membrane 4 CD4, CYP1B1, HLA-A, HLA-B
Mitochondrion membrane 1 ABCG2
Nucleus 2 ALB, SRY
cytosol 1 ALB
mitochondrial membrane 1 ABCG2
centrosome 1 ALB
nucleoplasm 2 ABCG2, SRY
Cell membrane 9 ABCB1, ABCG2, CD4, CD8A, HLA-A, HLA-B, P2RX7, SELP, TNF
Early endosome membrane 2 HLA-A, HLA-B
Multi-pass membrane protein 3 ABCB1, ABCG2, P2RX7
cell surface 5 ABCB1, HLA-A, HLA-B, ICAM1, TNF
Golgi apparatus 3 ALB, HLA-A, HLA-B
Golgi membrane 3 HLA-A, HLA-B, INS
lysosomal membrane 2 HLA-A, HLA-B
neuromuscular junction 1 P2RX7
neuronal cell body 2 P2RX7, TNF
postsynapse 1 P2RX7
Presynapse 1 P2RX7
plasma membrane 13 ABCB1, ABCG2, CD4, CD8A, F2, HLA-A, HLA-B, ICAM1, IFNLR1, P2RX7, SELP, TNF, TNFRSF11B
Membrane 8 ABCB1, ABCG2, CYP1B1, HLA-A, HLA-B, ICAM1, IFNLR1, P2RX7
apical plasma membrane 2 ABCB1, ABCG2
extracellular exosome 7 ABCB1, ALB, F2, HLA-A, HLA-B, ICAM1, SELP
Lysosome membrane 2 HLA-A, HLA-B
endoplasmic reticulum 3 ALB, HLA-A, HLA-B
extracellular space 11 ALB, CRP, F2, HLA-A, HLA-B, ICAM1, IL6, INS, SELP, TNF, TNFRSF11B
mitochondrion 2 CYP1B1, P2RX7
protein-containing complex 1 ALB
intracellular membrane-bounded organelle 1 CYP1B1
Microsome membrane 1 CYP1B1
Single-pass type I membrane protein 7 CD4, CD8A, HLA-A, HLA-B, ICAM1, IFNLR1, SELP
Secreted 7 ALB, CRP, F2, IL6, INS, SELP, TNFRSF11B
extracellular region 9 ALB, CD8A, CRP, F2, IL6, INS, SELP, TNF, TNFRSF11B
Single-pass membrane protein 2 HLA-A, HLA-B
[Isoform 2]: Secreted 1 CD8A
anchoring junction 1 ALB
external side of plasma membrane 8 CD4, CD8A, HLA-A, HLA-B, ICAM1, P2RX7, SELP, TNF
Early endosome 1 CD4
cell-cell junction 1 P2RX7
recycling endosome 1 TNF
Single-pass type II membrane protein 1 TNF
Apical cell membrane 2 ABCB1, ABCG2
Membrane raft 4 ABCG2, CD4, ICAM1, TNF
focal adhesion 1 ICAM1
extracellular matrix 1 TNFRSF11B
collagen-containing extracellular matrix 2 F2, ICAM1
nuclear speck 1 SRY
receptor complex 2 CD8A, TNFRSF11B
ciliary basal body 1 ALB
chromatin 1 SRY
phagocytic cup 1 TNF
phagocytic vesicle membrane 2 HLA-A, HLA-B
centriole 1 ALB
brush border membrane 1 ABCG2
spindle pole 1 ALB
blood microparticle 2 ALB, F2
Recycling endosome membrane 2 HLA-A, HLA-B
endosome lumen 1 INS
Nucleus speckle 1 SRY
platelet dense granule membrane 1 SELP
plasma membrane raft 1 CD8A
secretory granule lumen 1 INS
secretory granule membrane 1 HLA-B
Golgi lumen 2 F2, INS
endoplasmic reticulum lumen 5 ALB, CD4, F2, IL6, INS
platelet alpha granule lumen 1 ALB
transport vesicle 1 INS
Endoplasmic reticulum-Golgi intermediate compartment membrane 1 INS
endoplasmic reticulum exit site 1 HLA-A
immunological synapse 1 ICAM1
ER to Golgi transport vesicle membrane 2 HLA-A, HLA-B
clathrin-coated endocytic vesicle membrane 1 CD4
external side of apical plasma membrane 2 ABCB1, ABCG2
lumenal side of endoplasmic reticulum membrane 2 HLA-A, HLA-B
MHC class I peptide loading complex 1 HLA-A
[Isoform 1]: Cell membrane 1 CD8A
platelet alpha granule membrane 1 SELP
Golgi medial cisterna 1 HLA-A
bleb 1 P2RX7
[Tumor necrosis factor, soluble form]: Secreted 1 TNF
T cell receptor complex 2 CD4, CD8A
MHC class I protein complex 2 HLA-A, HLA-B
MHC class II protein complex 2 HLA-A, HLA-B
platelet dense granule lumen 1 SELP
interleukin-6 receptor complex 1 IL6
ciliary transition fiber 1 ALB
interleukin-28 receptor complex 1 IFNLR1
[C-domain 2]: Secreted 1 TNF
[Tumor necrosis factor, membrane form]: Membrane 1 TNF
[C-domain 1]: Secreted 1 TNF


文献列表

  • Sandra Rotea-Salvo, Víctor Giménez-Arufe, Alejandro Martínez-Pradeda, Carla Fernández-Oliveira, Álvaro Mena-de-Cea, Luis Margusino-Framiñán, Isabel Martín-Herranz, Purificación Cid-Silva. Lipid profile changes associated with antiretroviral therapies in a real-world cohort. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 2023 Sep; 47(5):T210-T217. doi: 10.1016/j.farma.2023.07.005. [PMID: 37673703]
  • Sandra Rotea-Salvo, Víctor Giménez-Arufe, Alejandro Martínez-Pradeda, Carla Fernández-Oliveira, Álvaro Mena-de-Cea, Luis Margusino-Framiñán, Isabel Martín-Herranz, Purificación Cid-Silva. Lipid profile changes associated with antiretroviral therapies in a real-world cohort. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 2023 Jun; ?(?):. doi: 10.1016/j.farma.2023.04.007. [PMID: 37349200]
  • P N Kunene, P N Mahlambi. Case study on antiretroviral drugs uptake from soil irrigated with contaminated water: Bio-accumulation and bio-translocation to roots, stem, leaves, and fruits. Environmental pollution (Barking, Essex : 1987). 2023 Feb; 319(?):121004. doi: 10.1016/j.envpol.2023.121004. [PMID: 36608725]
  • Lucy Campbell, Fowzia Ibrahim, Birgit Barbini, Amanda Samarawickrama, Chloe Orkin, Julie Fox, Laura Waters, Yvonne Gilleece, Shema Tariq, Frank A Post. Bone mineral density, kidney function and participant-reported outcome measures in women who switch from tenofovir disoproxil emtricitabine and a nonnucleoside reverse transcriptase inhibitor to abacavir, lamivudine and dolutegravir. HIV medicine. 2022 04; 23(4):362-370. doi: 10.1111/hiv.13215. [PMID: 34866304]
  • Leonardo Calza, Giorgio Legnani, Ciro Fulgaro, Gabriella Verucchi, Isabella Bon, Tiziana Lazzarotto, Pierluigi Viale. Changes in Serum Inflammatory Markers in Antiretroviral Therapy-Naive HIV-Infected Patients Starting Dolutegravir/Lamivudine or Dolutegravir/Lamivudine/Abacavir. Journal of acquired immune deficiency syndromes (1999). 2022 03; 89(3):e30. doi: 10.1097/qai.0000000000002861. [PMID: 34743087]
  • E A Illarionova, N V Chmelevskaya, Yu A Gonchikova, A E Mitina. [Determination of abacavir in biological objects for the purpose of chemical and toxicological analysis]. Sudebno-meditsinskaia ekspertiza. 2022; 65(2):29-33. doi: 10.17116/sudmed20226502129. [PMID: 35416013]
  • Z C Lim, G S Hoo, J H Ang, C B Teng, L W Ang, C C Lee, Y S Leo, H L Law, O T Ng, C S Wong. Safety and effectiveness of switching to Abacavir/Lamivudine plus rilpivirine for maintenance therapy in virologically suppressed HIV-1 individuals in Singapore (SEALS). AIDS research and therapy. 2021 11; 18(1):80. doi: 10.1186/s12981-021-00402-7. [PMID: 34724931]
  • Rajendra P Singh, Kimberly Adkison, Allen Wolstenholme, Judy Hopking, Brian Wynne. Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Abacavir/Dolutegravir/Lamivudine Combination Tablets in Healthy Japanese Study Participants. Clinical pharmacology in drug development. 2021 09; 10(9):985-993. doi: 10.1002/cpdd.996. [PMID: 34265164]
  • Wouter A van der Heijden, Jun Wan, Lisa Van de Wijer, Martin Jaeger, Mihai G Netea, Andre J van der Ven, Philip G de Groot, Mark Roest, Quirijn de Mast. Plasmatic Coagulation Capacity Correlates With Inflammation and Abacavir Use During Chronic HIV Infection. Journal of acquired immune deficiency syndromes (1999). 2021 05; 87(1):711-719. doi: 10.1097/qai.0000000000002633. [PMID: 33492017]
  • Prashanth Chowdary, Shraddha Shetty, John Booth, Muhammad Arslan Khurram, Magdi Yaqoob, Ismail Heyder Mohamed. Experience of SARS-CoV-2 infection in two kidney transplant recipients living with HIV-1 infection. Transplant infectious disease : an official journal of the Transplantation Society. 2021 Apr; 23(2):e13500. doi: 10.1111/tid.13500. [PMID: 33174284]
  • Agnieszka Matuszewska, Beata Nowak, Wojciech Niżański, Maria Eberhardt, Kinga Domrazek, Anna Nikodem, Benita Wiatrak, Krzysztof Zduniak, Kamil Olejnik, Anna Merwid-Ląd, Tomasz Tomkalski, Diana Jędrzejuk, Ewa Szeląg, Marzenna Podhorska-Okołów, Aleksandra Piotrowska, Izabela Jęśkowiak, Agata Heinrich, Maria Rutkowska, Wojciech Dziewiszek, Tomasz Sozański, Joanna Kwiatkowska, Paulina Jawień, Marek Bolanowski, Adam Szeląg. Long-Term Administration of Abacavir and Etravirine Impairs Semen Quality and Alters Redox System and Bone Metabolism in Growing Male Wistar Rats. Oxidative medicine and cellular longevity. 2021; 2021(?):5596090. doi: 10.1155/2021/5596090. [PMID: 34373766]
  • Sanjeev Kumar, Himanshu Batra, Swarandeep Singh, Himanshi Chawla, Ravinder Singh, Sanket Katpara, Abdul Wahid Hussain, Bimal Kumar Das, Rakesh Lodha, Sushil Kumar Kabra, Kalpana Luthra. Effect of combination antiretroviral therapy on human immunodeficiency virus 1 specific antibody responses in subtype-C infected children. The Journal of general virology. 2020 12; 101(12):1289-1299. doi: 10.1099/jgv.0.001480. [PMID: 32915123]
  • Steffen Jockusch, Chuanjuan Tao, Xiaoxu Li, Thomas K Anderson, Minchen Chien, Shiv Kumar, James J Russo, Robert N Kirchdoerfer, Jingyue Ju. A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19. Antiviral research. 2020 08; 180(?):104857. doi: 10.1016/j.antiviral.2020.104857. [PMID: 32562705]
  • Eisuke Adachi, Makoto Saito, Kazuhiko Ikeuchi, Tokio Hoshina, Hiroshi Yotsuyanagi. Cases of coronavirus disease-2019 in HIV-infected transgender women. AIDS (London, England). 2020 07; 34(9):1435-1436. doi: 10.1097/qad.0000000000002573. [PMID: 32590441]
  • Chloe Orkin, Edwin DeJesus, Paul E Sax, Jose R Arribas, Samir K Gupta, Claudia Martorell, Jeffrey L Stephens, Hans-Jurgen Stellbrink, David Wohl, Franco Maggiolo, Melanie A Thompson, Daniel Podzamczer, Debbie Hagins, Jason A Flamm, Cynthia Brinson, Amanda Clarke, Hailin Huang, Rima Acosta, Diana M Brainard, Sean E Collins, Hal Martin. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials. The lancet. HIV. 2020 06; 7(6):e389-e400. doi: 10.1016/s2352-3018(20)30099-0. [PMID: 32504574]
  • Aude Jary, Anne-Geneviève Marcelin, Charlotte Charpentier, Marc Wirden, Minh P Lê, Gilles Peytavin, Diane Descamps, Vincent Calvez. M184V/I does not impact the efficacy of abacavir/lamivudine/dolutegravir use as switch therapy in virologically suppressed patients. The Journal of antimicrobial chemotherapy. 2020 05; 75(5):1290-1293. doi: 10.1093/jac/dkaa019. [PMID: 32065630]
  • Neha Agrawal, Jennifer Rowe, Jie Lan, Qigui Yu, Christine A Hrycyna, Jean Chmielewski. Potential Tools for Eradicating HIV Reservoirs in the Brain: Development of Trojan Horse Prodrugs for the Inhibition of P-Glycoprotein with Anti-HIV-1 Activity. Journal of medicinal chemistry. 2020 03; 63(5):2131-2138. doi: 10.1021/acs.jmedchem.9b00779. [PMID: 31505928]
  • Akiko Fukuda, Takako Nagao, Tomomi Kitaichi, Ichiro Koga, Akihiro Kobayashi, Toshiyuki Miura. Safety analysis of Lexiva tablets 700 (fosamprenavir calcium hydrate) in post-marketing surveillance in Japan. Current medical research and opinion. 2020 03; 36(3):455-464. doi: 10.1080/03007995.2019.1700495. [PMID: 31794279]
  • Marta Fernández-González, José A García, Sergio Padilla, Javier García-Abellán, Vanesa Agulló, Félix Gutiérrez, Mar Masiá. Rectal and seminal HIV-1 RNA decay towards virological suppression in infected MSM initiating dolutegravir/abacavir/lamivudine. The Journal of antimicrobial chemotherapy. 2020 03; 75(3):668-674. doi: 10.1093/jac/dkz482. [PMID: 31769846]
  • Yusuke Marikawa, Hong-Ru Chen, Mark Menor, Youping Deng, Vernadeth B Alarcon. Exposure-based assessment of chemical teratogenicity using morphogenetic aggregates of human embryonic stem cells. Reproductive toxicology (Elmsford, N.Y.). 2020 01; 91(?):74-91. doi: 10.1016/j.reprotox.2019.10.004. [PMID: 31711903]
  • Leonardo Calza, Michele Sachs, Vincenzo Colangeli, Marco Borderi, Bianca Granozzi, Pietro Malosso, Giorgia Comai, Valeria Corradetti, Gaetano La Manna, Pierluigi Viale. Prevalence of chronic kidney disease among HIV-1-infected patients receiving a combination antiretroviral therapy. Clinical and experimental nephrology. 2019 Nov; 23(11):1272-1279. doi: 10.1007/s10157-019-01768-9. [PMID: 31327092]
  • Laurent Hocqueloux, François Raffi, Thierry Prazuck, Louis Bernard, Simon Sunder, Jean-Luc Esnault, David Rey, Gwenaël Le Moal, Mariam Roncato-Saberan, Marie André, Eric Billaud, Antoine Valéry, Véronique Avettand-Fènoël, Jean-Jacques Parienti, Clotilde Allavena. Dolutegravir Monotherapy Versus Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed People Living With Chronic Human Immunodeficiency Virus Infection: The Randomized Noninferiority MONotherapy of TiviCAY Trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2019 10; 69(9):1498-1505. doi: 10.1093/cid/ciy1132. [PMID: 30601976]
  • Crystal R Leibrand, Jason J Paris, Austin M Jones, Quamrun N Masuda, Matthew S Halquist, Woong-Ki Kim, Pamela E Knapp, Angela D M Kashuba, Kurt F Hauser, MaryPeace McRae. HIV-1 Tat and opioids act independently to limit antiretroviral brain concentrations and reduce blood-brain barrier integrity. Journal of neurovirology. 2019 08; 25(4):560-577. doi: 10.1007/s13365-019-00757-8. [PMID: 31102185]
  • Lisa J Frigati, Karryn Brown, Sana Mahtab, Leah Githinji, Diane Gray, Liesl Zühlke, Peter Nourse, Dan J Stein, Jaqueline Hoare, Mark F Cotton, Landon Myer, Heather J Zar. Multisystem impairment in South African adolescents with Perinatally acquired HIV on antiretroviral therapy (ART). Journal of the International AIDS Society. 2019 08; 22(8):e25386. doi: 10.1002/jia2.25386. [PMID: 31441211]
  • David A Wohl, Yazdan Yazdanpanah, Axel Baumgarten, Amanda Clarke, Melanie A Thompson, Cynthia Brinson, Debbie Hagins, Moti N Ramgopal, Andrea Antinori, Xuelian Wei, Rima Acosta, Sean E Collins, Diana Brainard, Hal Martin. Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. The lancet. HIV. 2019 06; 6(6):e355-e363. doi: 10.1016/s2352-3018(19)30077-3. [PMID: 31068270]
  • Nongodo Firmin Kaboré, Armel Poda, Jacques Zoungrana, Ollo Da, Laura Ciaffi, Aoua Semdé, Issouf Yaméogo, Adrien B Sawadogo, Eric Delaporte, Nicolas Meda, Sophie Limou, Amandine Cournil. Chronic kidney disease and HIV in the era of antiretroviral treatment: findings from a 10-year cohort study in a west African setting. BMC nephrology. 2019 05; 20(1):155. doi: 10.1186/s12882-019-1335-9. [PMID: 31064340]
  • Sebastiano Rizzardo, Massimiliano Lanzafame, Emanuela Lattuada, Damiano Bragantini, Stefano Nicolè, Leonardo Calza, Evelina Tacconelli. Efficacy and safety of abacavir/lamivudine with raltegravir in treatment-experienced and treatment-naïve patients with HIV-1 infection: an observational, retrospective, multi-centre study. International journal of STD & AIDS. 2019 04; 30(5):467-471. doi: 10.1177/0956462418817049. [PMID: 30999834]
  • Sarah M Michienzi, Christopher A Schriever, Melissa E Badowski. Abacavir/lamivudine/dolutegravir single tablet regimen in patients with human immunodeficiency virus and end-stage renal disease on hemodialysis. International journal of STD & AIDS. 2019 02; 30(2):181-187. doi: 10.1177/0956462418800865. [PMID: 30381029]
  • Edgar Dehesa Lopez, Carlos Córdova-Cázarez, Rafael Valdez-Ortiz, Carlie Michelle Cardona-Landeros, María Fernanda Gutiérrez-Rico. Epidemiological, clinical, and laboratory factors associated with chronic kidney disease in Mexican HIV-infected patients. Jornal brasileiro de nefrologia : 'orgao oficial de Sociedades Brasileira e Latino-Americana de Nefrologia. 2019 Jan; 41(1):48-54. doi: 10.1590/2175-8239-jbn-2018-0024. [PMID: 30010693]
  • Gordana Dragovic, Katarina Nikolic, Bozana Dimitrijevic, Djordje Jevtovic, Dubravka Salemovic, Nada Tomanovic, Ivan Boricic. Severe hepatotoxicity induced by efavirenz in a treatment-naïve, low body mass index HIV-infected, female patient with no hepatitis and other virus co-infections. Ultrastructural pathology. 2019; 43(4-5):220-223. doi: 10.1080/01913123.2019.1673862. [PMID: 31578116]
  • Aleš Chrdle, Zdeňka Jerhotová, Michal Vacík, Marek Linka, Václav Chmelík. Crushed dolutegravir/abacavir/lamivudine given via nasogastric tube in gastric outlet obstruction caused by cancer resulted in rapid viral load suppression. International journal of STD & AIDS. 2019 01; 30(1):94-98. doi: 10.1177/0956462418797847. [PMID: 30231834]
  • Rajendra P Singh, Jafar S B Shaik, Nancy Skoura, Shashidhar Joshi, Trevor Shreeves, Linda Casillas, Ann M Buchanan. Effects of Low- and High-Mineral Content Water on the Relative Bioavailability of a Coformulated Abacavir/Dolutegravir/Lamivudine Dispersible Tablet in Healthy Adults. Journal of acquired immune deficiency syndromes (1999). 2018 12; 79(5):631-638. doi: 10.1097/qai.0000000000001859. [PMID: 30239425]
  • Lukas Cerveny, Zuzana Ptackova, Martina Ceckova, Rona Karahoda, Sara Karbanova, Lucie Jiraskova, Susan L Greenwood, Jocelyn D Glazier, Frantisek Staud. Equilibrative Nucleoside Transporter 1 (ENT1, SLC29A1) Facilitates Transfer of the Antiretroviral Drug Abacavir across the Placenta. Drug metabolism and disposition: the biological fate of chemicals. 2018 11; 46(11):1817-1826. doi: 10.1124/dmd.118.083329. [PMID: 30097436]
  • Jean-Michel Molina, Douglas Ward, Indira Brar, Anthony Mills, Hans-Jürgen Stellbrink, Luis López-Cortés, Peter Ruane, Daniel Podzamczer, Cynthia Brinson, Joseph Custodio, Hui Liu, Kristen Andreatta, Hal Martin, Andrew Cheng, Erin Quirk. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. The lancet. HIV. 2018 07; 5(7):e357-e365. doi: 10.1016/s2352-3018(18)30092-4. [PMID: 29925489]
  • A Calcagno, C Pinnetti, A De Nicolò, E Scarvaglieri, M Gisslen, M Tempestilli, A D'Avolio, V Fedele, G Di Perri, A Antinori, S Bonora. Cerebrospinal fluid abacavir concentrations in HIV-positive patients following once-daily administration. British journal of clinical pharmacology. 2018 06; 84(6):1380-1383. doi: 10.1111/bcp.13552. [PMID: 29444348]
  • Richard A Elion, Keri N Althoff, Jinbing Zhang, Richard D Moore, Stephen J Gange, Mari M Kitahata, Heidi M Crane, Daniel R Drozd, James H Stein, Marina B Klein, Joseph J Eron, Michael J Silverberg, William C Mathews, Amy C Justice, Timothy R Sterling, Charles S Rabkin, Angel M Mayor, Daniel B Klein, Michael A Horberg, Ronald J Bosch, Oghenowede Eyawo, Frank J Palella. Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV. Journal of acquired immune deficiency syndromes (1999). 2018 05; 78(1):62-72. doi: 10.1097/qai.0000000000001642. [PMID: 29419568]
  • Jane A O'Halloran, Eimear Dunne, Willard Tinago, Stephanie Denieffe, Dermot Kenny, Patrick W G Mallon. Switching from abacavir to tenofovir disoproxil fumarate is associated with rises in soluble glycoprotein VI, suggesting changes in platelet-collagen interactions. AIDS (London, England). 2018 04; 32(7):861-866. doi: 10.1097/qad.0000000000001783. [PMID: 29438200]
  • Catherine Orrell, Debbie P Hagins, Elena Belonosova, Norma Porteiro, Sharon Walmsley, Vicenç Falcó, Choy Y Man, Alicia Aylott, Ann M Buchanan, Brian Wynne, Cindy Vavro, Michael Aboud, Kimberly Y Smith. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study. The lancet. HIV. 2017 12; 4(12):e536-e546. doi: 10.1016/s2352-3018(17)30095-4. [PMID: 28729158]
  • Roberta Gagliardini, Massimiliano Fabbiani, Manuela Colafigli, Alessandro D'Avino, Annalisa Mondi, Alberto Borghetti, Silvia Lamonica, Roberto Cauda, Andrea De Luca, Simona Di Giambenedetto. Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients. Journal of chemotherapy (Florence, Italy). 2017 Oct; 29(5):299-307. doi: 10.1080/1120009x.2016.1269040. [PMID: 28019192]
  • Josef Reznicek, Martina Ceckova, Zuzana Ptackova, Ondrej Martinec, Lenka Tupova, Lukas Cerveny, Frantisek Staud. MDR1 and BCRP Transporter-Mediated Drug-Drug Interaction between Rilpivirine and Abacavir and Effect on Intestinal Absorption. Antimicrobial agents and chemotherapy. 2017 09; 61(9):. doi: 10.1128/aac.00837-17. [PMID: 28696229]
  • Samir K Gupta, Eunice Yeh, Douglas W Kitch, Todd T Brown, Charles S Venuto, Gene D Morse, Belinda Ha, Kathleen Melbourne, Grace A McComsey. Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s. The Journal of antimicrobial chemotherapy. 2017 07; 72(7):2042-2048. doi: 10.1093/jac/dkx076. [PMID: 28369419]
  • Eiko Yamada, Ritsuo Takagi, Yoshinari Tanabe, Hiroshi Fujiwara, Naoki Hasegawa, Shingo Kato. Plasma and saliva concentrations of abacavir, tenofovir, darunavir, and raltegravir in HIV-1-infected patients
. International journal of clinical pharmacology and therapeutics. 2017 Jul; 55(7):567-570. doi: 10.5414/cp202789. [PMID: 28427498]
  • Yacouba L Diallo, Véronique Ollivier, Véronique Joly, Dorothée Faille, Giovanna Catalano, Martine Jandrot-Perrus, Antoine Rauch, Patrick Yeni, Nadine Ajzenberg. Abacavir has no prothrombotic effect on platelets in vitro. The Journal of antimicrobial chemotherapy. 2016 12; 71(12):3506-3509. doi: 10.1093/jac/dkw303. [PMID: 27516475]
  • Suresh K A, Kadiam C Venkata Subbaiah, Rayapu Lavanya, Kuruva Chandrasekhar, Naga Raju Chamarti, M Suresh Kumar, Rajendra Wudayagiri, Lokanatha Valluru. Design, Synthesis and Biological Evaluation of Novel Phosphorylated Abacavir Derivatives as Antiviral Agents Against Newcastle Disease Virus Infection in Chicken. Applied biochemistry and biotechnology. 2016 Sep; 180(2):361-81. doi: 10.1007/s12010-016-2104-x. [PMID: 27142273]
  • Pasquale Pagliano, Tiziana Ascione, Maria Aurora Carleo, Giovanni Boccia, Francesco De Caro, Fabio Tortora. HIV positive patient with HSV-2 encephalitis: case report. Le infezioni in medicina. 2016 Sep; 24(3):245-9. doi: NULL. [PMID: 27668908]
  • Josep M Llibre, Andrew Hill. Abacavir and cardiovascular disease: A critical look at the data. Antiviral research. 2016 08; 132(?):116-21. doi: 10.1016/j.antiviral.2016.05.015. [PMID: 27260856]
  • Victor Musiime, Philip Kasirye, Bethany Naidoo-James, Patricia Nahirya-Ntege, Tawanda Mhute, Adrian Cook, Lincoln Mugarura, Marshall Munjoma, Navdeep K Thoofer, Emmanuel Ndashimye, Immaculate Nankya, Moira J Spyer, Margaret J Thomason, Wendy Snowden, Diana M Gibb, Ann Sarah Walker. Once vs twice-daily abacavir and lamivudine in African children. AIDS (London, England). 2016 07; 30(11):1761-70. doi: 10.1097/qad.0000000000001116. [PMID: 27064996]
  • Edward J Fuchs, Jennifer J Kiser, Craig W Hendrix, Mark Sulkowski, Christine Radebaugh, Lane Bushman, Michelle L Ray, Adriana Andrade. Plasma and intracellular ribavirin concentrations are not significantly altered by abacavir in hepatitis C virus-infected patients. The Journal of antimicrobial chemotherapy. 2016 06; 71(6):1597-600. doi: 10.1093/jac/dkw009. [PMID: 26869690]
  • Stein Schalkwijk, Angela Colbers, Deborah Konopnicki, Katharina Weizsäcker, José Moltó, Carmen Hidalgo Tenorio, David Hawkins, Graham Taylor, Chris Wood, Marchina van der Ende, David Burger. The pharmacokinetics of abacavir 600 mg once daily in HIV-1-positive pregnant women. AIDS (London, England). 2016 05; 30(8):1239-44. doi: 10.1097/qad.0000000000001046. [PMID: 26836789]
  • J Young, I Mucsi, K C Rollet-Kurhajec, M B Klein. Fibroblast growth factor 23: associations with antiretroviral therapy in patients co-infected with HIV and hepatitis C. HIV medicine. 2016 May; 17(5):373-9. doi: 10.1111/hiv.12305. [PMID: 26307135]
  • Julia L Marcus, Romain S Neugebauer, Wendy A Leyden, Chun R Chao, Lanfang Xu, Charles P Quesenberry, Daniel B Klein, William J Towner, Michael A Horberg, Michael J Silverberg. Use of Abacavir and Risk of Cardiovascular Disease Among HIV-Infected Individuals. Journal of acquired immune deficiency syndromes (1999). 2016 Apr; 71(4):413-9. doi: 10.1097/qai.0000000000000881. [PMID: 26536316]
  • Zoi Terzopoulou, Myrsini Papageorgiou, George Z Kyzas, Dimitrios N Bikiaris, Dimitra A Lambropoulou. Preparation of molecularly imprinted solid-phase microextraction fiber for the selective removal and extraction of the antiviral drug abacavir in environmental and biological matrices. Analytica chimica acta. 2016 Mar; 913(?):63-75. doi: 10.1016/j.aca.2016.01.059. [PMID: 26944990]
  • Silvia A Guillemi, Sean H Ling, Julia S Dahlby, Benita Yip, Wendy Zhang, Mark W Hull, Viviane Dias Lima, Robert S Hogg, Ronald Werb, Julio S Montaner, Marianne Harris. Effects of a switch from tenofovir- to abacavir-based antiretroviral therapy, with or without atazanavir, on renal function. Journal of the International AIDS Society. 2016; 19(1):20995. doi: 10.7448/ias.19.1.20995. [PMID: 27624144]
  • Oscar Cirioni, Sefora Castelletti, Claudio Ucciferri, Katia Falasca, Elena Orsetti, Susanna Mazzocato, Chiara Valeriani, Francesco Maria Di Campli, Francesco Barchiesi, Jacopo Vecchiet, Andrea Giacometti. Antiretroviral therapy management and rationalisation of available resources. Le infezioni in medicina. 2015 Dec; 23(4):330-5. doi: . [PMID: 26700083]
  • Zuzana Neumanova, Lukas Cerveny, Susan L Greenwood, Martina Ceckova, Frantisek Staud. Effect of drug efflux transporters on placental transport of antiretroviral agent abacavir. Reproductive toxicology (Elmsford, N.Y.). 2015 Nov; 57(?):176-82. doi: 10.1016/j.reprotox.2015.07.070. [PMID: 26169552]
  • Eiko Yamada, Ritsuo Takagi, Koji Sudo, Shingo Kato. Determination of abacavir, tenofovir, darunavir, and raltegravir in human plasma and saliva using liquid chromatography coupled with tandem mass spectrometry. Journal of pharmaceutical and biomedical analysis. 2015 Oct; 114(?):390-7. doi: 10.1016/j.jpba.2015.06.005. [PMID: 26112927]
  • Valentine Wanga, Charles Venuto, Gene D Morse, Edward P Acosta, Eric S Daar, David W Haas, Chun Li, Bryan E Shepherd. Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202. Pharmacogenetics and genomics. 2015 Sep; 25(9):450-61. doi: 10.1097/fpc.0000000000000156. [PMID: 26148204]
  • Aaron W Michels, David A Ostrov. New approaches for predicting T cell-mediated drug reactions: A role for inducible and potentially preventable autoimmunity. The Journal of allergy and clinical immunology. 2015 Aug; 136(2):252-7. doi: 10.1016/j.jaci.2015.06.024. [PMID: 26254052]
  • Kishore Cholkar, Hoang M Trinh, Aswani Dutt Vadlapudi, Zhiying Wang, Dhananjay Pal, Ashim K Mitra. Interaction Studies of Resolvin E1 Analog (RX-10045) with Efflux Transporters. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics. 2015 May; 31(4):248-55. doi: 10.1089/jop.2014.0144. [PMID: 25844889]
  • Karen Andrade-Fuentes, José A Mata-Marín, José I López-De León, Bulmaro Manjarrez-Téllez, Jorge L Sandoval Ramírez, Jesús Gaytan-Martínez. Proximal renal tubular dysfunction related to antiretroviral therapy among HIV-infected patients in an HIV clinic in Mexico. AIDS patient care and STDs. 2015 Apr; 29(4):181-5. doi: 10.1089/apc.2014.0134. [PMID: 25101526]
  • Mark A Boyd, Cecilia L Moore, Jean-Michel Molina, Robin Wood, Juan S Madero, Marcelo Wolff, Kiat Ruxrungtham, Marcelo Losso, Boris Renjifo, Hedy Teppler, Anthony D Kelleher, Janaki Amin, Sean Emery, David A Cooper. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis. The lancet. HIV. 2015 Feb; 2(2):e42-51. doi: 10.1016/s2352-3018(14)00061-7. [PMID: 26424460]
  • David S Lehmann, Heather J Ribaudo, Eric S Daar, Roy M Gulick, Richard H Haubrich, Gregory K Robbins, Paul I W de Bakker, David W Haas, Paul J McLaren. Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols. Pharmacogenetics and genomics. 2015 Feb; 25(2):51-9. doi: 10.1097/fpc.0000000000000106. [PMID: 25461247]
  • H G Sprenger, N Langebeek, P G H Mulder, C H H Ten Napel, R Vriesendorp, A I M Hoepelman, J C Legrand, P P Koopmans, B Bravenboer, R W Ten Kate, Php Groeneveld, Wfw Bierman, Ts van der Werf, Eh Gisolf, C Richter. A randomized controlled trial of single-class maintenance therapy with abacavir/lamivudine/zidovudine after standard triple antiretroviral induction therapy: final 96-week results from the FREE study. HIV medicine. 2015 Feb; 16(2):122-31. doi: 10.1111/hiv.12186. [PMID: 25472825]
  • Pauline Bollen, Peter Reiss, Jonathan Schapiro, David Burger. Clinical pharmacokinetics and pharmacodynamics of dolutegravir used as a single tablet regimen for the treatment of HIV-1 infection. Expert opinion on drug safety. 2015; 14(9):1457-72. doi: 10.1517/14740338.2015.1059818. [PMID: 26134478]
  • Juan Peris-Vicente, Mónica Villareal-Traver, Inmaculada Casas-Breva, Samuel Carda-Broch, Josep Esteve-Romero. A micellar liquid chromatography method for the quantification of abacavir, lamivudine and raltegravir in plasma. Journal of pharmaceutical and biomedical analysis. 2014 Sep; 98(?):351-5. doi: 10.1016/j.jpba.2014.06.009. [PMID: 24996008]
  • Pablo Tebas, Michael Sension, José Arribas, Dan Duiculescu, Eric Florence, Chien-Ching Hung, Timothy Wilkin, Simon Vanveggel, Marita Stevens, Henri Deckx. Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2014 Aug; 59(3):425-34. doi: 10.1093/cid/ciu234. [PMID: 24729492]
  • Lee Faulkner, Xiaoli Meng, B Kevin Park, Dean J Naisbitt. The importance of hapten-protein complex formation in the development of drug allergy. Current opinion in allergy and clinical immunology. 2014 Aug; 14(4):293-300. doi: 10.1097/aci.0000000000000078. [PMID: 24936850]
  • Jose Vicente Fernandez-Montero, Pablo Barreiro, Pablo Labarga, Carmen De Mendoza, Vicente Soriano. Dolutegravir, abacavir and lamivudine as HIV therapy. Expert opinion on pharmacotherapy. 2014 May; 15(7):1051-7. doi: 10.1517/14656566.2014.913023. [PMID: 24754315]
  • Xiaoli Meng, Alexandre S Lawrenson, Neil G Berry, James L Maggs, Neil S French, David J Back, Saye H Khoo, Dean J Naisbitt, B Kevin Park. Abacavir forms novel cross-linking abacavir protein adducts in patients. Chemical research in toxicology. 2014 Apr; 27(4):524-35. doi: 10.1021/tx400406p. [PMID: 24571427]
  • Victor Musiime, Adrian Cook, Joshua Kayiwa, Dorothy Zangata, Carol Nansubuga, Beatrice Arach, Julia Kenny, Priscilla Wavamunno, Justine Komunyena, Desiree Kabamba, Alice R Asiimwe, Grace Mirembe, George Abongomera, Veronica Mulenga, Adeodata Kekitiinwa, Cissy Kityo, Sarah A Walker, Nigel Klein, Diana M Gibb. Anthropometric measurements and lipid profiles to detect early lipodystrophy in antiretroviral therapy experienced HIV-infected children in the CHAPAS-3 trial. Antiviral therapy. 2014; 19(3):269-76. doi: 10.3851/imp2695. [PMID: 24717427]
  • Louis R Spiegel, Peter B Schrier, Hitesh H Shah. Severe recurrent rhabdomyolysis-induced acute kidney injury in a HIV-infected patient on antiretroviral therapy. Renal failure. 2013 Sep; 35(8):1186-90. doi: 10.3109/0886022x.2013.817316. [PMID: 23883141]
  • Mario Cruciani, Carlo Mengoli, Giovanni Serpelloni, Saverio G Parisi, Marina Malena, Oliviero Bosco. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV. The Cochrane database of systematic reviews. 2013 Jun; ?(6):CD008270. doi: 10.1002/14651858.cd008270.pub2. [PMID: 23740608]
  • Wei Zhao, Chiara Piana, Meindert Danhof, David Burger, Oscar Della Pasqua, Evelyne Jacqz-Aigrain. Population pharmacokinetics of abacavir in infants, toddlers and children. British journal of clinical pharmacology. 2013 Jun; 75(6):1525-35. doi: 10.1111/bcp.12024. [PMID: 23126277]
  • Muki S Shey, Eugene J Kongnyuy, Samuel M Alobwede, Charles Shey Wiysonge. Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS. The Cochrane database of systematic reviews. 2013 Mar; ?(3):CD005481. doi: 10.1002/14651858.cd005481.pub3. [PMID: 23543540]
  • Roger L Shapiro, Steven Rossi, Anthony Ogwu, Mary Moss, Jean Leidner, Claire Moffat, Shahin Lockman, Sikhulile Moyo, Joseph Makhema, Max Essex, Edmund Capparelli. Therapeutic levels of lopinavir in late pregnancy and abacavir passage into breast milk in the Mma Bana Study, Botswana. Antiviral therapy. 2013; 18(4):585-90. doi: 10.3851/imp2474. [PMID: 23183881]
  • Caroline Solas, Elodie Pambrun, Maria Winnock, Dominique Salmon, Isabelle Poizot-Martin, Stéphanie Dominguez, Firouzé Bani-Sadr, Jacques Izopet, Rodolphe Garraffo, Gilles Peytavin. Ribavirin and abacavir drug interaction in HIV-HCV coinfected patients: fact or fiction?. AIDS (London, England). 2012 Nov; 26(17):2193-9. doi: 10.1097/qad.0b013e32835763a4. [PMID: 22781224]
  • Magdalena Monika Dabrowska, Tomasz Mikula, Alicja Wiercinska-Drapalo. HCV coinfection possibly promotes left ventricular dysfunction development: analysis of brain natriuretic peptide serum levels in HCV/HIV-coinfected and HIV-monoinfected patients. European journal of gastroenterology & hepatology. 2012 Nov; 24(11):1308-12. doi: 10.1097/meg.0b013e32835702c6. [PMID: 22825646]
  • L Gallelli, O Staltari, C Palleria, G Di Mizio, G De Sarro, B Caroleo. A case of adverse drug reaction induced by dispensing error. Journal of forensic and legal medicine. 2012 Nov; 19(8):497-8. doi: 10.1016/j.jflm.2012.04.026. [PMID: 23084317]
  • Murali Krishna Matta, Laxminarayana Burugula, Nageswara Rao Pilli, Jaswanth Kumar Inamadugu, Seshagiri Rao J V L N. A novel LC-MS/MS method for simultaneous quantification of tenofovir and lamivudine in human plasma and its application to a pharmacokinetic study. Biomedical chromatography : BMC. 2012 Oct; 26(10):1202-9. doi: 10.1002/bmc.2679. [PMID: 22222724]
  • Maricelle O Monteagudo-Chu, Mei H Chang, Horatio B Fung, Norbert Bräu. Renal toxicity of long-term therapy with tenofovir in HIV-infected patients. Journal of pharmacy practice. 2012 Oct; 25(5):552-9. doi: 10.1177/0897190012442718. [PMID: 22551561]
  • Massimo Cella, Meindert Danhof, Oscar Della Pasqua. Adaptive trials in paediatric development: dealing with heterogeneity and uncertainty in pharmacokinetic differences in children. British journal of clinical pharmacology. 2012 Aug; 74(2):346-53. doi: 10.1111/j.1365-2125.2012.04187.x. [PMID: 22256787]
  • Wei Zhao, Massimo Cella, Oscar Della Pasqua, David Burger, Evelyne Jacqz-Aigrain. Population pharmacokinetics and maximum a posteriori probability Bayesian estimator of abacavir: application of individualized therapy in HIV-infected infants and toddlers. British journal of clinical pharmacology. 2012 Apr; 73(4):641-50. doi: 10.1111/j.1365-2125.2011.04121.x. [PMID: 21988586]
  • Mar Masiá, Sergio Padilla, Catalina Robledano, Natividad López, José Manuel Ramos, Felix Gutiérrez. Early changes in parathyroid hormone concentrations in HIV-infected patients initiating antiretroviral therapy with tenofovir. AIDS research and human retroviruses. 2012 Mar; 28(3):242-6. doi: 10.1089/aid.2011.0052. [PMID: 21639815]
  • P Kasirye, L Kendall, K K Adkison, C Tumusiime, M Ssenyonga, S Bakeera-Kitaka, P Nahirya-Ntege, T Mhute, A Kekitiinwa, W Snowden, D M Burger, D M Gibb, A S Walker. Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1. Clinical pharmacology and therapeutics. 2012 Feb; 91(2):272-80. doi: 10.1038/clpt.2011.225. [PMID: 22190066]
  • Jan van Lunzen, Franco Maggiolo, José R Arribas, Aza Rakhmanova, Patrick Yeni, Benjamin Young, Jürgen K Rockstroh, Steve Almond, Ivy Song, Cindy Brothers, Sherene Min. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. The Lancet. Infectious diseases. 2012 Feb; 12(2):111-8. doi: 10.1016/s1473-3099(11)70290-0. [PMID: 22018760]
  • Giuseppe Pontrelli, Nicola Cotugno, Donato Amodio, Paola Zangari, Hyppolite K Tchidjou, Stefania Baldassari, Paolo Palma, Stefania Bernardi. Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitors. BMC infectious diseases. 2012 Jan; 12(?):18. doi: 10.1186/1471-2334-12-18. [PMID: 22269183]
  • Gerard Aragonès, Pedro Pardo-Reche, Laura Fernández-Sender, Anna Rull, Raúl Beltrán-Debón, Esther Rodríguez-Gallego, Jordi Camps, Jorge Joven, Carlos Alonso-Villaverde. The deleterious influence of tenofovir-based therapies on the progression of atherosclerosis in HIV-infected patients. Mediators of inflammation. 2012; 2012(?):372305. doi: 10.1155/2012/372305. [PMID: 22645407]
  • Pragna Patel, Tim Bush, Turner Overton, Jason Baker, John Hammer, Erna Kojic, Lois Conley, Keith Henry, John T Brooks. Effect of abacavir on acute changes in biomarkers associated with cardiovascular dysfunction. Antiviral therapy. 2012; 17(4):755-61. doi: 10.3851/imp2020. [PMID: 22301072]
  • Akil Jackson, Graeme Moyle, Laura Dickinson, David Back, Saye Khoo, Jessica Taylor, Keerti Gedela, George Abongomera, Brian Gazzard, Marta Boffito. Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects. Antiviral therapy. 2012; 17(1):19-24. doi: 10.3851/imp1910. [PMID: 22267465]
  • Thomas A Rasmussen, Danny Jensen, Martin Tolstrup, Ulla S Nielsen, Erland J Erlandsen, Henrik Birn, Lars Østergaard, Bente L Langdahl, Alex L Laursen. Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial. PloS one. 2012; 7(3):e32445. doi: 10.1371/journal.pone.0032445. [PMID: 22479327]
  • Marilia Rita Pinzone, Michelino Di Rosa, Bruno Cacopardo, Giuseppe Nunnari. HIV RNA suppression and immune restoration: can we do better?. Clinical & developmental immunology. 2012; 2012(?):515962. doi: 10.1155/2012/515962. [PMID: 22489250]
  • José R Santos, José Moltó, Josep M Llibre, Eugenia Negredo, Isabel Bravo, Arelly Ornelas, Bonaventura Clotet, Roger Paredes. Antiretroviral simplification with darunavir/ritonavir monotherapy in routine clinical practice: safety, effectiveness, and impact on lipid profile. PloS one. 2012; 7(5):e37442. doi: 10.1371/journal.pone.0037442. [PMID: 22666357]
  • M Chini, A B Tsoupras, N Mangafas, N Tsogas, V D Papakonstantinou, E Fragopoulou, S Antonopoulou, P Gargalianos, C A Demopoulos, M C Lazanas. Effects of highly active antiretroviral therapy on platelet activating factor metabolism in naive HIV-infected patients: ii) study of the abacavir/lamivudine/efavirenz HAART regimen. International journal of immunopathology and pharmacology. 2012 Jan; 25(1):247-58. doi: 10.1177/039463201202500127. [PMID: 22507337]
  • Yu Ming Paul Lam, Kristin L McBride, Janaki Amin, Damien V Cordery, Anthony D Kelleher, David A Cooper, Kersten K Koelsch. Switching virally suppressed, treatment-experienced patients to a raltegravir-containing regimen does not alter levels of HIV-1 DNA. PloS one. 2012; 7(3):e31990. doi: 10.1371/journal.pone.0031990. [PMID: 22396745]
  • Amit C Achhra, Janaki Amin, Jennifer Hoy, Junko Tanuma, Thira Sirisanthana, David Nolan, Tuti Merati, Michelle Giles. Differences in lipid measurements by antiretroviral regimen exposure in cohorts from Asia and australia. AIDS research and treatment. 2012; 2012(?):246280. doi: 10.1155/2012/246280. [PMID: 22675613]
  • Luis F López-Cortés, Rosa Ruiz-Valderas, Luis Jimenez-Jimenez, María F González-Escribano, Almudena Torres-Cornejo, Rosario Mata, Antonio Rivero, Juan A Pineda, Manuel Marquez-Solero, Pompeyo Viciana. Influence of IL28B polymorphisms on response to a lower-than-standard dose peg-IFN-α 2a for genotype 3 chronic hepatitis C in HIV-coinfected patients. PloS one. 2012; 7(1):e28115. doi: 10.1371/journal.pone.0028115. [PMID: 22235243]
  • Kirsty C McGee, Mohsen Shahmanesh, Meg Boothby, Peter Nightingale, Laura L Gathercole, Gyanendra Tripathi, Alison L Harte, Fariba Shojaee-Moradie, A Margot Umpleby, Satyajit Das, Nasser M Al-Daghri, Philip G McTernan, Jeremy W Tomlinson. Evidence for a shift to anaerobic metabolism in adipose tissue in efavirenz-containing regimens for HIV with different nucleoside backbones. Antiviral therapy. 2012; 17(3):495-507. doi: 10.3851/imp2017. [PMID: 22300946]
  • Georg Behrens, Renato Maserati, Armin Rieger, Pere Domingo, Florian Abel, Hui Wang, Gill Pearce. Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles. Antiviral therapy. 2012; 17(6):1011-20. doi: 10.3851/imp2305. [PMID: 22910324]
  • Paolo Maggi, Vincenzo Montinaro, Chiara Bellacosa, Stefania Pietanza, Anna Volpe, Giusi Graziano, Giovanni F M Strippoli, Gioacchino Angarano. Early markers of tubular dysfunction in antiretroviral-experienced HIV-infected patients treated with tenofovir versus abacavir. AIDS patient care and STDs. 2012 Jan; 26(1):5-11. doi: 10.1089/apc.2011.0185. [PMID: 22136504]